An otherwise healthy 61-year-old female presented with a skin tumor on the left flank, which had been present since her early adulthood. The tumor gradually enlarged during the first 2-3 years and then stabilized in size. There were no symptoms from the tumor. On examination, a red to violaceous, shiny, polypoid, fusiform nodule with firm consis tency, measuring approximately 3.0 cm × 2.0 cm, was noted on her left flank (Figure 1 ). There were also many skin tumors on her face and scalp, most of which were dome-shaped, smooth surfaced, violaceous, firm nodules measuring several millimeters in diameter. These tumors were 1-cm dermal nodules that caused pain; others were rounded, skin-colored, firm papules with a size of approximately 5 mm in diameter around her nose. An excisional biopsy specimen was obtained from the tumor at the flank.
Diagnosis
Cylindroma and Brooke-Spiegler syndrome.
Discussion
Cylindroma is a common benign adnexal tumor, which is most often seen on the head, neck and scalp. It usually presents as a dome-shaped, shiny nodule. Scalp lesions may grow to a large size and coalescence of numerous lesions is known as a "turban tumor." Development on the trunk or polypoid appearance is exceptional. There is a marked female preponderance of cylindroma (up to 9:1). Familial cases have been described and are typically associated with multiple tumors. Multiple cylindromas may be associated with trichoepitheliomas and spiradenomas, a constellation known as Brooke-Spiegler syndrome, which is inherited in an autosomal dominant fashion. 1 Patients with this syndrome occasionally develop multiple basal cell adenomas, milia, organoid nevi, and basal cell carcinoma. There is a high penetrance in affected families, but the individual clinical manifestation is highly variable. Brooke-Spiegler syndrome is caused by germline mutations in a single gene, called CYLD, located on chromosome 16q12-q13. Most of the mutations, which are mainly located at the C-terminal half of the CYLD coding sequence, lead to the formation of truncated proteins. 2 The function of CYLD is not fully understood. It belongs to a family of ubiquitin-specific proteases, and interacts with NEMO, the regulatory subunit of the inhibitor κB kinase complex, tumor necrosis factor receptor-associated factors (TRAFs), and TRAFinteracting proteins; it negatively regulates the nuclear factor κB signal transduction pathway. Inhibition of CYLD enhances activation of the nuclear factor κB and leads to increased resistance to apoptosis and advanced carcinogenesis. 3 Mutation screening of the CYLD gene should be considered for patients with multiple cylindromas and/or trichoepitheliomas, as well as for their relatives. Early identification of Brooke-Spiegler syndrome may improve therapeutic management to avoid complications such as disfigurement and malignant transformation. 3 Treatment modalities of these tumors reported in the literature are mainly ablative, including surgical removal, cryotherapy, electrodessication, topical trichloroacetic acid application, and CO 2 and Er:YAG laser. 4 It has been reported that the effect of CYLD mutation can be reversed by application of salicylates or prostaglandin A. 5 This finding may provide directions for future novel therapy for this syndrome.
